Bioengineered Protein Drugs Market
Bioengineered Protein Drugs Market (Drug Type - Monoclonal Antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, and Synazis), Therapeutic Proteins (Hormones, Cytokines, Blood Factor, Enzyme Therapy, and Thrombolytics), and Vaccines; Disease Condition - Cancer, Diabetes, Autoimmune Disorder, Infectious Disease, Hematopoiesis, CVD, and Neurodegenerative; End User - Pharmaceutical and Biotechnology Companies, CROs, and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
Press Release :
Bioengineered Protein Drugs Market - Snapshot
Bioengineering is the application of engineering technology and methods to the field of biology. Polymer of amino acids, proteins play a significant role in facilitating smooth functioning of the human body. With the utilization of genetic engineering procedure, bioengineered proteins are synthesized. These proteins are also known as recombinant protein, which is used in the treatment of many illnesses. Wide scope of application is likely to bolster the growth of the global bioengineered protein drugs market. Bioengineered protein drugs are utilized in the treatment of various chronic conditions such as
- Blood disorders
- Fertility disorders
- Immunological disorders
- Hormonal disorders
Bioengineered protein drugs are considered extremely efficient with much improved pharmacodynamic (PD) and Pharmacokinetic (PK) characteristics. These drugs come with better matching with biological processes and thus have minimum side effects and wider acceptance. This factor is likely to drive the growth of the global bioengineered protein drugs market in the years to come.
Advancement in the Biopharmaceutical Field to Stoke Demand in the Market
The global bioengineered protein drugs market is also likely to be driven by the immense technological and research-based progress made in the biopharmaceuticals field. In addition, a rise in the prevalence of chronic diseases is estimated to drive the demand for bioengineered protein drugs.
The drugs fare better than small molecule drugs in terms of the time taken for receiving approval from FDA. Bioengineered protein drugs takes much less time, which is a significant factor in driving the market over the tenure of assessment. In accordance with the findings of world health organization (WHO), it is estimated that the number of people suffering from diabetes with rise to 36 million by 2030. However, complication is involved in the treatment of diseases utilizing bioengineered protein drugs is likely to restrain the growth of the global bioengineered protein drugs market. Furthermore, the rising cost of these drugs is predicted to come up as another factor hampering development of the market in near future.
Global Bioengineered Protein Drugs Market: Snapshot
Majorly fuelling the global bioengineered protein drugs market is the rising occurrence of infectious diseases, diabetes, cancer, etc. This is because bioengineered protein drugs are more effective and additionally have reduced or no side effects when compared with alternative therapies for cancer, diabetes, and other maladies. This has led to more healthcare physicians prescribing these drugs, thereby stoking demand in the market.
The prospects in the global market for bioengineered protein drugs also looks upbeat owing to increasing drugs in phase III of clinical trials and many companies pouring money into research and development of novel bioengineered proteins.
Posing a roadblock to the market, on the other hand, is the steep cost of manufacturing bioengineered protein drug, having shorter shelf life. The emergence of biosimilars is also posing a severe challenge to the growth in the market.
A report by Transparency Market Research predicts the global bioengineered protein drugs market to expand at a 7.4% CAGR from 2017 to 2024 to become worth US$336.9 bn by 2025 from US$177.7 bn in 2016.
Vaccines Slated to Grow at Maximum Pace due to Development of Bioengineered Prophylactic Vaccines
The global bioengineered protein drugs market can be classified into monoclonal antibodies, vaccines, and therapeutic protein based upon the type of product. The therapeutic protein segment, among them, accounts for a dominant share because of extensive activities in the therapeutic protein engineering and recombinant DNA technology products. In terms of growth rate, however, the vaccines segment is expected to outshine all other segments by clocking maximum CAGR between 2017 to 2025 because of increase in development of bioengineered prophylactic and therapeutics vaccines.
Rising Instances of Cancer Propels North America Market to Fore
From a geographical standpoint, North America leads the global bioengineered protein drugs market. In the years ahead, the region is slated is maintain its dominant position because of the rising occurrence of cancer and unveiling of innovative protein therapeutics for cancer. While loss of patents of blockbuster drugs such as Humira, Rituxan, Avastin, and Remicade, among others, are expected to deal a blow to the revenue in the market, launch of new drugs and approvals for new diagnostic tests, along with a growing geriatric population and unhealthy lifestyle will likely make up for it by inducing growth. As per the TMR report, the bioengineered protein drugs market in North America will likely register a CAGR of 7.2% from 2017 to 2025 to become worth US$161.05 bn by 2025.
Though trailing North America, in terms of size, Europe is expected to lag behind all other regions vis-à-vis growth rate because of the patent loss of blockbuster drugs such as Humira, Avastin, and Lucentis and emergence of biosimilars.
Powered by India, China, and South Korea, Asia Pacific is expected to steal the show in the near future by expanding at a maximum CAGR of 9.0% from 2017 to 2025. Growing occurrence of cancer, massive investments by players, and rapid rise in healthcare infrastructure are said to be boosting growth in the region. China is at the forefront of driving growth in the region because of the sizeable proportion cancer patients, increasing geriatric population, launch of premium-priced targeted therapies, and rise in number of people covered under private health insurance in the country.
Some of the key players in the global bioengineered protein drugs market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Amgen, Inc., Bayer AG, Merck & Co., Inc., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Eli Lilly and Company, Sanofi, GlaxoSmithKline plc, Johnson & Johnson (JanssenNovartis AG, Panacea Biotec, and ProBioGen AG.
Global Bioengineered Protein Drugs Market: Overview
This report provides in-depth region wise and country wise analysis of the bioengineered protein drugs market. Stakeholders of this report include manufacturers of bioengineered protein drugs, raw material suppliers, research institutes involve in the research of bioengineered protein drugs and new players planning to enter the market.
The report provides qualitative and quantitative analysis of the global bioengineered protein drugs market. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market information. Quantitative analysis includes major players with their reported revenue, market size, and forecast for the global bioengineered protein drugs market in major countries globally such as the U.S., Canada, Germany, Italy, France, United Kingdom, Spain, Japan, China, Brazil, Mexico, South Africa and GCC countries. Market revenue is provided in terms of US$ Mn from 2015 to 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 for all the segments, considering 2016 as the base year. The executive summary of the report provides a snapshot of the bioengineered protein drugs with information on leading segments, country wise market information with respect to the market size, growth rate (CAGR %), and growth factors.
The market overview section comprises impact factors such as drivers, restraints, and opportunities for the global bioengineered protein drugs market. These factors would aid the stakeholders in establishing a strong foothold in the global bioengineered protein drugs market. Furthermore, the market overview section comprises key industry events, product overview, market attractiveness analysis and emerging trend in the bioengineered protein drugs market. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments and country wise to identify the most attractive market.
Global Bioengineered Protein Drugs Market: Segmentation
The bioengineered protein drugs market has been segmented as by drug type, by disease condition, by end-user and by geography. Based on drug type, the market has been segmented into monoclonal antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, Synazis, and Others) therapeutic proteins (hormones, cytokines, blood factor, enzyme therapy, thrombolytics, and others) vaccines. Based on disease condition, the market has been segmented into cancer, diabetes, autoimmune disorder, infectious disease, hematopoiesis, CVD, neurodegenerative, and others. Based on end-user, the market has been segmented into pharmaceutical & biotechnology companies, CROs, research institutes.
Global Bioengineered Protein Drugs Market: Geographical Analysis
Geographically, the bioengineered protein drugs market has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, analysis for the major countries comprising U.S. Canada, Germany, Italy, France, U.K., Spain, Rest of Europe, Japan, China, India, Rest of APAC, Brazil, Mexico, Rest of LATAM, South Africa, GCC countries have also been provided in the report. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the bioengineered protein drugs market in various regions has been provided in this section.
This report also includes various ups and downs about particular country or geography that has impacted the overall market globally.
Global Bioengineered Protein Drugs Market: Competitive Analysis
The report provides a detailed outline/blueprint of the bioengineered protein drugs market globally that will assist new companies in establishing their presence and market players in expanding their market share in the market. The report concludes with the company profile section which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Merck & Co., Inc., Reliance Life Sciences Pvt. Ltd., Panacea Biotech, ProBioGen AG, GlaxoSmithKline plc., and F. Hoffmann-La Roche Ltd
The global Bioengineered Protein Drugs market has been segmented into:
by Drug Type
by Disease Condition